

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DMI BioSciences, Inc.	04/16/2009
RECEIVING PARTY DATA	
Name:	DMI Acquisition Corp.
Street Address:	The Quadrant
Internal Address:	5445 DTC Parkway, Suite 925
City:	Greenwood Village
State/Country:	COLORADO
Postal Code:	80111
PROPERTY NUMBERS Total: 65	
Property Type	Number
Application Number:	60157404
Application Number:	09678202
Application Number:	10076071
Application Number:	12562136
Application Number:	13100854
Application Number:	13100870
Application Number:	13571532
Application Number:	10186168
Application Number:	10894860
Application Number:	11781439
Application Number:	11930090
Application Number:	11930099
Application Number:	11930103
Application Number:	11930106

Application Number:	11930114
Application Number:	11930116
Application Number:	11930117
Application Number:	12610508
Application Number:	13110550
Application Number:	09922234
Application Number:	10397964
Application Number:	13248422
Application Number:	13252377
Application Number:	13338056
Application Number:	13338441
Application Number:	09732474
Application Number:	09922604
Application Number:	07911159
Application Number:	10099132
Application Number:	10199285
Application Number:	10300664
Application Number:	60434692
Application Number:	60417741
Application Number:	60464471
Application Number:	60496360
Application Number:	10680935
Application Number:	13341608
Application Number:	60429924
Application Number:	10723247
Application Number:	13152072
Application Number:	13152089
Application Number:	60468797
Application Number:	10840943
Application Number:	60471017
Application Number:	60489270
Application Number:	60514930
Application Number:	60517338
Application Number:	10846482
Application Number:	12707942

	12707958
Application Number:	13247782
Application Number:	12753671
Application Number:	13676932
Application Number:	13676966
Application Number:	13676984
Application Number:	13677007
Application Number:	13679599
Application Number:	10679699
Application Number:	12499063
Application Number:	13622202
Application Number:	10949715
Application Number:	11368031
Application Number:	11457063
Application Number:	13072545
Application Number:	13072568

CORRESPONDENCE DATA

Fax Number: 3038630223

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 303-863-9700

Email: aduarte@sheridanross.com

Correspondent Name: Sheridan Ross P.C.

Address Line 1: 1560 Broadway

Address Line 2: Suite 1200

Address Line 4: Denver, COLORADO 80202

ATTORNEY DOCKET NUMBER:

6134-106

NAME OF SUBMITTER:

Angela M. Domitrovich

Total Attachments: 49

source=Patent Assignment (DMI Bio to DMI Acqu)#page1.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page2.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page3.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page4.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page5.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page6.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page7.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page8.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page9.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page10.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page11.tif

PATENT
REEL: 029565 FRAME: 0275

source=Patent Assignment (DMI Bio to DMI Acqu)#page12.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page13.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page14.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page15.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page16.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page17.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page18.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page19.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page20.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page21.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page22.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page23.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page24.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page25.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page26.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page27.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page28.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page29.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page30.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page31.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page32.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page33.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page34.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page35.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page36.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page37.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page38.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page39.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page40.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page41.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page42.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page43.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page44.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page45.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page46.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page47.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page48.tif
source=Patent Assignment (DMI Bio to DMI Acqu)#page49.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "*Assignment*") is entered into by and among DMI BioSciences, Inc., a Colorado corporation ("*Assignor*"), and DMI Acquisition Corp., a Delaware corporation ("*Assignee*"), as of April 16, 2009 (the "*Effective Date*"). Assignor and Assignee may hereinafter be referred to individually as a "*Party*," and together, the "*Parties*." Capitalized terms used but not otherwise defined herein shall have the meanings assigned to them in the Purchase Agreement (as defined below).

WHEREAS, Assignor owns the patents and patent applications, as set forth in Schedule A attached hereto and incorporated herein by this reference (collectively, the "*Patents*").

WHEREAS, Assignor, Assignee and DMI Life Sciences, Inc., a Delaware corporation, have entered into an Asset Purchase Agreement, dated as of the date hereof (the "*Purchase Agreement*"), pursuant to which Assignor sold to Assignee, and Assignee acquired from Assignor, all right, title and interest to and in all of the Acquired Assets, including, without limitation, the rights in the Patents.

NOW, THEREFORE, for good and valuable consideration as set forth in the Purchase Agreement, the receipt and sufficiency of which hereby is acknowledged:

1. Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to Assignee all of Assignor's right, title and interest in and to the Patents (and regarding Patents that are patent applications, any patents that may issue therefrom), including any foreign counterparts, patents or patent applications to which the Patents claim priority, divisionals, continuations in whole or in part, reexaminations, reissues or extensions thereof, and the right to claim priority to any of the preceding, the same to be held by Assignee for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all claims for damages by reason of past infringements of the Patents and the right to sue for and collect such damages, as permitted under the applicable laws for any jurisdiction or country in which such claims may be asserted, for the use and benefit of Assignee and its successors, assigns and other legal representatives.

2. Assignor hereby authorizes and requests the Commissioner for Patents or the Director of the United States Patent & Trademark Office, and any officer of any country or countries foreign to the United States whose duty it is to issue patents or other evidence or forms of intellectual property protection or applications as aforesaid, to issue the same to Assignee and its successors, assigns and other legal representatives in accordance with the terms of this instrument.

3. Assignor hereby constitutes and appoints Assignee as Assignor's true and lawful attorney in fact, with full power of substitution in Assignor's name and stead, to take any and all steps, including proceedings at law, in equity or otherwise, to execute, acknowledge and deliver any and all instruments and assurances necessary or expedient in order to vest or perfect the aforesaid rights and causes of action more effectively in Assignee or to protect the same or to enforce any claim or right of any kind with respect thereto. Assignor hereby declares that the foregoing power is coupled with an interest and as such is irrevocable.

4. If any provision of this Assignment shall be adjudged by any court of competent jurisdiction to be unenforceable or invalid, that provision shall be limited or eliminated to the minimum extent necessary so that this Assignment shall otherwise remain in full force and effect and enforceable. This Assignment shall be deemed to have been made in and shall be construed pursuant to the laws of the State of Delaware and the United States America without regard to conflicts of laws provisions thereof.

5. Assignor hereby covenants that it has full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreements inconsistent herewith.

[Remainder of page intentionally left blank. Signature page(s) to follow.]

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed as a sealed instrument by its duly authorized officer as of the date first written above.


ASSIGNOR: DMI BIOSCIENCES, INC.
Signature: Bruce Miller
Name: BRUCE MILLER
Title: PRESIDENT & CEO

NOTARIZATION

On this 16th day of APRIL, 2009, before me, the undersigned Notary Public, personally appeared BRUCE MILLER, proved to me through satisfactory evidence of identification, which was/were ECHO DRIVER'S LICENSE, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of ASSIGNOR and executed this document of his/her own free will.

[Signature]
Signature of Notary

My Commission Expires: OCTOBER 9TH, 2011



ASSIGNEE: DMI ACQUISITION CORP.
Signature: _____
Name: _____
Title: _____

On this ____ day of _____, 2009, before me, the undersigned Notary Public, personally appeared _____, proved to me through satisfactory evidence of identification, which was/were _____, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of ASSIGNEE and executed this document of his/her own free will.

Signature of Notary

My Commission Expires: _____

(Seal)

SIGNATURE PAGE TO
PATENT ASSIGNMENT

PATENT
REEL: 029565 FRAME: 0279

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed as a sealed instrument by its duly authorized officer as of the date first written above.

ASSIGNOR: DMI BIOSCIENCES, INC.

Signature: _____
Name: _____
Title: _____

NOTARIZATION

On this ____ day of _____, 2009, before me, the undersigned Notary Public, personally appeared _____, proved to me through satisfactory evidence of identification, which was/were _____, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of ASSIGNOR and executed this document of his/her own free will.

(Seal)

Signature of Notary

My Commission Expires: _____

ASSIGNEE: DMI ACQUISITION CORP.

Signature: _____
Name: _____
Title: _____


On this 19th day of May, 2009, before me, the undersigned Notary Public, personally appeared Michael Macaluso, proved to me through satisfactory evidence of identification, which was/were CO DL, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of ASSIGNEE and executed this document of his/her own free will.

(Seal)

Signature of Notary

My Commission Expires: My Commission expires 12/26/2010

SIGNATURE PAGE TO
PATENT ASSIGNMENT



SCHEDULE A

Patents

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3PROV	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler	The invention is directed to metal-binding peptides and peptide derivatives and their use to inhibit the formation or accumulation of reactive oxygen species (ROS) in order to reduce or prevent the damage caused by the ROS	Provisional application no. 60/157,404; filed October 1, 1999 Procedures completed
4172-3PROV-1	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler	The invention is directed to metal-binding peptides and peptide derivatives and their use to inhibit the formation or accumulation of reactive oxygen species (ROS) in order to reduce or prevent the damage caused by the ROS and to reduce levels of metal ions	Provisional application no. 60/211,078; filed June 13, 2000 Procedures completed
4172-3	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	The invention is directed to an expanded group of metal-binding peptides and peptide derivatives and to peptide dimers and the use of all of these compounds to inhibit the formation or accumulation of reactive oxygen species (ROS) in order to reduce or prevent the damage caused by the ROS and to reduce levels of metal ions	U.S. nonprovisional application no. 09/678,202; filed September 29, 2000 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-PCT	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3	PCT application no. PCT/US00/26952; filed September 30, 2000. Published as WO 01/25265 Nationalized
4172-3-PAU	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Australian application 77,407/00 Patent no. 770999, granted 4/14/05; expires 9/29/20
4172-3-PBR	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Brazilian application PI0014389-8 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-PCA	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Canadian application 2,385,551
4172-3-PCN	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Chinese application 00815718.9
4172-3-PEP	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	EP application 00967163.7

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-PHK	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Hong Kong application 03103218.7
4172-3-PIN	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Indian application IN/PCT/2002/00324/DEL
4172-3-PIN-DIV	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Indian application 7380/DELNP/2008

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-PIL	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Israeli application 148,797
4172-3-PJP	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Japanese application 2001-528205
4172-3-PKR	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	South Korean application 10-2002-7004228

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-PNZ	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	New Zealand application 518266 New Zealand patent number 518266; granted 5/12/05 Abandoned
4172-3-PSG	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	Singapore application 200201500-6 Singapore patent number 87657; granted 4/30/04 Abandoned
4172-3-PZA	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-PCT	South African application 2002/3310 South African patent number 2002/3310; granted 12/31/03 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3PROV-2	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Provisional application directed particularly to use of compounds of 4172-3 to reduce DNA damage and telomere shortening caused by ROS	Provisional application no. 60/268,558; filed February 13, 2001 Procedures completed
4172-3-1PROV	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation-in-part of 4172-3 to add disclosure of 4172-3PROV-2 and other extensions and developments	Provisional application no. 60/509,045; (formerly nonprovisional application no. 09/816,679); filed March 22, 2001 Procedures completed
4172-3PROV-3	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation-in-part of 4172-3-1PROV to add disclosure, extensions and developments	Provisional application no. 60/281,648; filed April 4, 2001 Procedures completed

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3PROV-4	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation-in-part of 4172-3PROV-3 to add disclosure, extensions and developments	Provisional application no. 60/283,507; filed April 11, 2001 Procedures completed
4172-3-2	Metal-Binding Compounds And Uses Therefor; David Bar-Or	Same as 4172-3PROV-4 except no peptidomimetics and added some material, primarily angiogenesis	Nonprovisional U.S. application no. 10/076,071, filed 2/13/02 Have been notified by examiner that claims are allowable
4172-3-2-PCT	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3PROV-4 except no peptidomimetics and added some material, primarily angiogenesis	PCT application no. PCT/US02/04275, filed 2/13/02 Published as WO 02/64620 Not nationalized
4172-3-3	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-2, except added new experiments re inflammation and new peptides	Nonprovisional U.S. application no. 10/186,168, filed 6/27/02 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-4	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Same as 4172-3-3, except added new experiments re new peptides	Nonprovisional U.S. application no. 10/894,860, filed 7/19/04
4172-3-4-1	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/781,439, filed July 23, 2007 Abandoned
4172-3-4-2	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,090, filed October 31, 2007 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-4-3	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,099, filed October 31, 2007 Abandoned
4172-3-4-4	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,103, filed October 31, 2007 Abandoned
4172-3-4-5	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,106, filed October 31, 2007 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-3-4-6	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,114, filed October 31, 2007 Abandoned
4172-3-4-7	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,116, filed October 31, 2007 Abandoned
4172-3-4-8	Metal-Binding Compounds And Uses Therefor; David Bar-Or C. Gerald Curtis Edward Lau Nagaraja K.R. Rao James V. Winkler Wannell M. Crook	Continuation of 4172-3-4	Nonprovisional U.S. application no. 11/930,117, filed October 31, 2007 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-4PROV	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	The invention is directed to pharmaceutical compositions comprising a group of diketopiperazines and to methods of using the diketopiperazines to treat a disease or condition mediated by platelet activating factor (PAF), to inhibit inflammation, to inhibit the production or release of IL-8, to inhibit aggregation of platelets, and to inhibit the effects of PAF	Provisional application no. 60/222,849; filed August 4, 2000 Procedures completed
4172-4	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	See 4172-4PROV	Nonprovisional application no. 09/922,234; filed August 2, 2001 U.S. Patent No. 6,555,543 issued on 4/29/03; expires 8/2/21
4172-4-1	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	Continuation of 4172-4	Nonprovisional application no. 10/397,964; filed March 25, 2003
4172-4-PCT	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	See 4172-4PROV	PCT application no. PCT/US01/41541; filed August 2, 2001 Published as WO 02/11676 Nationalized

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-4-PAU	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	Australian application 2001 279 313 Patent No. 2001 279 313 granted 6/17/07; expires 8/2/21
4172-4-PBR	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	Brazilian application PI 0112969-4
4172-4-PCA	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	Canadian application 2,417,960
4172-4-PCN	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	Chinese application 01815837.4

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-4-PEP	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	European application 01957581.0
4172-4-PJP	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	Japanese application 2002-517014
4172-4-PZA	Method of Using Diketopiperazines; David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas	National phase of 4172-4-PCT	South African application 2003/0934 Patent 2003/0934 granted August 25, 2004; expires 8/2/21
4172-17	Method for the Very Rapid Detection of Polyamines; David Bar-Or Clive Solomons	U.S. Patent No. 5,330,898	U.S. Patent No. 5,330,898; issued July 19, 1994; expires 10/3/11
4172-23PROV	Processing Of Mass Spectrometry Spectra; Raphael Bar-Or	Processing of mass spectrometry data using linear programming	Provisional application no. 60/169,178; filed 12/6/99 Procedures completed

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-23	Noise Reducing/Resolution Enhancing Signal Processing Method And System; Raphael Bar-Or	Signal processing method and system for reducing noise and enhancing resolution of signal data from, e.g., a spectrometer	Nonprovisional application no. 09/732,464; filed 12/6/00 Issued as U.S. Patent No. 6,615,162 September 2, 2003; expires 1/18/22
4172-23-PCT	Noise Reducing/Resolution Enhancing Signal Processing Method And System; Raphael Bar-Or	Signal processing method and system for reducing noise and enhancing resolution of signal data from, e.g., a spectrometer	PCT application no. PCT/US00/33139; filed 12/6/00 Application not nationalized
4172-36PROV	Method Of Synthesizing Diketopiperazines; Nagaraja K.R. Rao Stephen Turner	This invention is directed to a method of synthesizing diketopiperazines wherein one of the amino acids is Asp or Glu; see 4172-4PROV	Provisional application no. 60/223,075; filed August 4, 2000 Procedures completed
4172-36	Method Of Synthesizing Diketopiperazines; Nagaraja K.R. Rao Stephen Turner	See 4172-36PROV	Nonprovisional application no. 09/922,604; filed August 2, 2001 U.S. Patent No. 6,967,202 issued 11/22/05; expires 7/21/22
4172-36-PCT	Method Of Synthesizing Diketopiperazines; Nagaraja K.R. Rao Stephen Turner	See 4172-36PROV	PCT application no. PCT/US01/24281; filed August 2, 2001 Nationalized

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-36-PGB	Method Of Synthesizing Diketopiperazines; Nagaraja K.R. Rao Stephen Turner	National phase of 4172-36-PCT	UK application 0301542.7 UK patent number 2,382,346; granted 8/11/04; expires 8/2/21
4172-42-1	Detection Of Appendicitis By Measurement Of Orthohydroxyhippuric Acid; David Bar-Or	U.S. Patent No. 5,470,750 directed to detection of appendicitis by measurement of orthohydroxyhippuric acid, including rule-out test	U.S. Patent No. 5,470,750; issued 11/28/95; expires 11/28/12
4172-43	Detection Of Appendicitis By Measurement Of Uroerythrin; David Bar-Or Stewart L. Greisman Jon G. Kastendieck	U.S. Patent No. 5,055,389 directed to detection of appendicitis by determining presence of uroerythrin	U.S. Patent No. 5,055,389 Expired

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-46PROV	System For Identifying Diagnostic And Therapeutic Compounds And Uses Therefor David Bar-Or Gerald Curtis Nagaraja K.R. Rao	Methods, kits, libraries of compounds and biological samples, and arrays of naturally-occurring, metal-binding proteins and peptides for identifying drug and diagnostic candidates. Also, using the drug and diagnostic candidates identified by these methods to treat and diagnose diseases. Further, using drug candidates shown to be effective to treat a disease to develop additional drug candidates for treating the disease through molecular modeling and rational drug design and to prepare databases of structural and chemical features that are important for the efficacy of drugs useful in treating the disease.	Provisional application no. 60/276,807 Procedures completed
4172-46PROV	System For Identifying Diagnostic And Therapeutic Compounds And Uses Therefor David Bar-Or Gerald Curtis Nagaraja K.R. Rao	Methods, kits, libraries of compounds and biological samples, and arrays of naturally-occurring, metal-binding proteins and peptides for identifying drug and diagnostic candidates. Also, using the drug and diagnostic candidates identified by these methods to treat and diagnose diseases. Further, using drug candidates shown to be effective to treat a disease to develop additional drug candidates for treating the disease through molecular modeling and rational drug design and to prepare databases of structural and chemical features that are important for the efficacy of drugs useful in treating the disease.	Nonprovisional application no. 10/099,132 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-69PROV	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Leonard Rael Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	Provisional application no. 60/307,005 filed July 19, 2001 Procedures completed
4172-69PROV-1	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Leonard Rael Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	Provisional application no. 60/344,514, filed December 28, 2001 Procedures completed
4172-69	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	U.S. nonprovisional application no. 10/199,285, filed July 19, 2002 Abandoned
4172-69-1	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	U.S. nonprovisional application no. 11/619,558, filed January 3, 2007 Continuation of 4172-69 Abandoned
4172-69-PCT	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	PCT application PCT/US02/22951 filed July 19, 2002 Nationalized

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-69-PEP	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	European application no. 2752462.8; filing date 7/19/02
4172-69-PIP	Use Of Copper Chelators To Reactivate Protein C; David Bar-Or Richard Yuki	Use of H4D and other copper chelators to reactivate protein C and to prevent the inactivation of protein C	Japanese application no. 2003-513312; filing date 7/19/02
4172-75PROV	Method Of Protecting Mouth Tissues; David Bar-Or	Method of protecting mouth tissues using metal chelators, especially copper chelators, which inhibit the formation and/or accumulation of ROS (see 4172-3 series of applications)	Provisional application no. 60/331,665 filed 11/20/01 Procedures complete
4172-75PROV-1	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Provisional application no. 60/360,736, filed 2/27/02 Procedures complete
4172-75	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Nonprovisional application no. 10/300,664, filed 11/19/02
4172-75-1	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Nonprovisional application no. 11/930,161, filed 10/31/07 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-75-2	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Nonprovisional application no. 11/930,165, filed 10/31/07 Abandoned
4172-75-PCT	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	PCT application no. PCT/US02/37136, filed 11/19/02 Published as WO 03/043518 Nationalized
4172-75-PAU	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Australian application 2002 348 301 Notice of acceptance; published for opposition
4172-75-PAU-DIV	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Australian application 2008 202 759
4172-75-PCA	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Canadian application 2,467,747
4172-75-PEP	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	EP application 02782326.9

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-75-PJP	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Japanese application 2003-545202 Abandoned
4172-75-PJP-DIV	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	Japanese application 2008-101024 Abandoned
4172-75-PNZ	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	New Zealand application 533595
4172-75-PNZ-DIV	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	New Zealand application 547077 Patent No. 547077 granted 8/14/08; expires 11/19/22
4172-75-PNZ-DIV-2	Method Of Protecting Mouth Tissues; David Bar-Or	Methods and products for oral care comprising compounds of 4172-3 series of applications	New Zealand application 563229
4172-78PROV	Improved Method Of Diagnosing Appendicitis; David Bar-Or Richard L. Yudel James V. Winkler Raphael Bar-Or	Improved method of diagnosing appendicitis by using combination of leukocyte count and AppyTest (OHHA)	Provisional application no. 60/341,977; filed December 18, 2001 No nonprovisional U.S. application or foreign applications filed; replaced by 4172-78-IPROV

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-78-PROV-1	Improved Method Of Diagnosing Appendicitis; David Bar-Or Richard L. Yuki James V. Winkler Raphael Bar-Or	Improved method of diagnosing appendicitis by using combination of measure inflammation and AppyTest (OHHA)	Provisional application no. 60/434,692; filed December 18, 2002 Nonprovisional U.S. application and PCT application filed -see 4172-81 and 4172-81-PCT
4172-79PROV	Method And Device for Removing Metal Ions From Fluids; David Bar-Or James V. Winkler Raphael Bar-Or	Method and device for removing metal ions from fluids comprising using an immobilized chelator	Provisional application no. 60/413,694; filed September 25, 2002 Abandoned
4172-79PROV-1	Method And Device for Removing Metal Ions From Fluids; David Bar-Or James V. Winkler Raphael Bar-Or	Method and device for removing metal ions from fluids comprising using an immobilized chelator	Provisional application no. 60/506,237; filed September 25, 2003 Abandoned
4172-80PROV	Diagnosis Of Multiple Sclerosis; David Bar-Or Raphael Bar-Or	Method of diagnosing and monitoring MS	Provisional application no. 60/415,908; filed October 2, 2002 Nonprovisional and foreign applications filed - see 4172-85 and 4172-85-PCT
4172-81PROV	Diagnosis Of Inflammation; David Bar-Or	Method of diagnosing and monitoring inflammation, both general and specific diseases by measuring phosphorylated proteins and peptides	Provisional application no. 60/417,741; filed October 9, 2002 Procedures complete

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-81PROV-1	Diagnosis Of Inflammation And Ischemia; David Bar-Or	Method of diagnosing and monitoring inflammation, both general and specific diseases, and method diagnosing ischemia by measuring phosphorylated proteins and peptides	Provisional application no. 60/464,471, filed April 21, 2003 Procedures complete
4172-81PROV-2	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or	Method of diagnosing and monitoring inflammation, both general and specific diseases, and method diagnosing ischemia, particularly placental ischemia, by measuring post-translationally modified proteins and peptides	Provisional application no. 60/489,169, filed July 21, 2003 Procedures complete
4172-81PROV-3	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or	Method of diagnosing and monitoring inflammation, both general and specific diseases, and method diagnosing ischemia, particularly placental ischemia, by measuring post-translationally modified proteins and peptides	Provisional application no. 60/496,360, filed August 18, 2003 Procedures complete
4172-81	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	Method of diagnosing and monitoring inflammation, both general and specific diseases, and method diagnosing ischemia, particularly placental ischemia, by measuring post-translationally modified proteins and peptides; improved method of diagnosing appendicitis	Nonprovisional U.S. application 10/680,935; filed October 2, 2003
4172-81-PCT	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	Method of diagnosing and monitoring inflammation, both general and specific diseases, and method diagnosing ischemia, particularly placental ischemia, by measuring post-translationally modified proteins and peptides; improved method of diagnosing appendicitis	PCT application US 03/31,468; filed October 2, 2003 Nationalized

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-81-PAU	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	See 4172-81-PCT	Australian application no. 2003299933
4172-81-PCA	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	See 4172-81-PCT	Canadian application no. 2,500,739
4172-81-PEP	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	See 4172-81-PCT	European Patent application no. 03808141.0
4172-81-PJP	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	See 4172-81-PCT	Japanese application no. 2005-501090

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-81-PNZ	Diagnosis Of Inflammation And Ischemia; David Bar-Or Raphael Bar-Or James V. Winkler Richard L. Yuki	See 4172-81-PCT	New Zealand application no. 539734
4172-81PROV-4	Diagnosis of Diabetes; David Bar-Or	Method of diagnosing and monitoring diabetes by measuring post-translationally modified insulin	Provisional application 60/562,724; filed 4/15/04 Abandoned
4172-82PROV	Treatment Of Inflammation; David Bar-Or	Method of treating inflammation utilizing extracellular phosphate-acceptor compounds	Provisional application no. 60/429,924, filed November 27, 2002 Procedures completed
4172-82	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	Method of treating diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. Also a method of inhibiting increased phosphorylation in cells, tissues and organs. The methods utilize phosphate-acceptor compounds	Nonprovisional U.S. application, serial no. 10/723,247, filed November 25, 2003
4172-82-PCT	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	Method of treating diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. Also a method of inhibiting increased phosphorylation in cells, tissues and organs. The methods utilize phosphate-acceptor compounds.	PCT application PCT/US03/37901; filed November 25, 2003 Nationalized

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-82-PAU	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Australian application number 2003299568
4172-82-PBR	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Brazilian application number PI 0315942-6 Abandoned
4172-82-PCA	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Canadian application number 2,507,051
4172-82-PCN	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Chinese application number 200380109316.4
4172-82-PEP	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	EP application number 03799853.1
4172-82-PEPHK	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PEP	HK application no. 06103092.5 corresponding to 4172-82-PEP; filed 3/10/06

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-82-PIN	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Indian application number 2846/DEL NP/2005 Notice of allowance received
4172-82-PIN-DIV	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Divisional Indian application
4172-82-PIL	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Israel application number 168775
4172-82-PIP	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Japanese application number 2004-557358
4172-82-PKR	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	S. Korean application number 5094398
4172-82-PNZ	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	New Zealand application number 540767

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-82-PSG	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Singapore application number 200503308.9 Abandoned
4172-82-PSG-DIV	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	Singapore divisional application number 200703595-9 Abandoned
4172-82-PSK	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	South Korean application number 10-2005-7009700
4172-82-PZA	Treatment Of Disease And Conditions Mediated By Increased Phosphorylation; David Bar-Or	See 4172-82-PCT	South African application number 2005/05113 Patent granted Abandoned
4172-83PROV	Trientine For Oral Care; Richard L. Yukul David Bar-Or	Use of trientine for oral care products	Provisional application no. 60/468,797, filed May 7, 2003 Procedures completed
4172-83	Oral Care Methods And Products; Richard L. Yukul David Bar-Or	Use of trientine and related compounds for oral care products	Nonprovisional US application 10/840,943, filed May 7, 2004

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-83-PCT	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	PCT application PCT/US04/14208, filed May 7, 2004 Nationalized
4172-83-PAU	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	Australian application no. 2004238285
4172-83-PBR	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	Brazilian application no. PI-0410505-2 Abandoned
4172-83-PCA	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	Canadian application no. 2,523,000
4172-83-PCN	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	Chinese application no. 200480012320.3
4172-83-PEP	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	European application no. 04751550.7

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-83-PEPHK	Oral Care Methods And Products; Richard L. Yukl David Bar-Or	Use of trientine and related compounds for oral care products	Registration of EPO application in HK
4172-83-PIL	Oral Care Methods And Products; Richard L. Yukl David Bar-Or	Use of trientine and related compounds for oral care products	Israeli application no. 171819
4172-83-PIN	Oral Care Methods And Products; Richard L. Yukl David Bar-Or	Use of trientine and related compounds for oral care products	Indian application no. 5410/DELNP/2005
4172-83-PIP	Oral Care Methods And Products; Richard L. Yukl David Bar-Or	Use of trientine and related compounds for oral care products	Japanese application no. 2006-532833
4172-83-PKR	Oral Care Methods And Products; Richard L. Yukl David Bar-Or	Use of trientine and related compounds for oral care products	Korean application no. 6015588
4172-83-PNZ	Oral Care Methods And Products; Richard L. Yukl David Bar-Or	Use of trientine and related compounds for oral care products	New Zealand application no. 542888

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-83-PSG	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	Singapore application no. 200506562-8
4172-83-PZA	Oral Care Methods And Products; Richard L. Yuki David Bar-Or	Use of trientine and related compounds for oral care products	South Africa application no 2005/08952
4172-84PROV	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Provisional application no. 60/471,017, filed May 15, 2003 Procedures complete
4172-84PROV-1	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Provisional application no. 60/489,270, filed July 21, 2003 Procedures complete
4172-84PROV-2	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Provisional application no. 60/514,930, filed October 27, 2003 Procedures complete

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-84PROV-3	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Provisional application no. 60/517,338, filed November 4, 2003 Procedures complete
4172-84	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	U.S. nonprovisional application 10/846,482, filed May 14, 2004
4172-84-PCT	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	PCT application PCT/US2004/15340, filed May 14, 2004 Nationalized
4172-84-PAU	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Australian application no. 2004241101, filed May 14, 2004
4172-84-PBR	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Brazil application no. PI-0410506-0 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-84-PCA	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Canada application no. 2,523,467
4172-84-PCN	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	China application no. 200480013249.0
4172-84-PCN-DIV-1	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	China application no. 200810081995.3
4172-84-PEP	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	EPO application no. 04752368.2
4172-84-PEPHK	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Application no. 06108488.6; registration of EPO application in HK

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-84-PIN	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	India application no. 5484/DELNP/2005
4172-84-PIL	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Israel application no. 171961
4172-84-PIP	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Japan application no. 2006-533125
4712-84-PKR	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	South Korea application no. 10-2005-7021755
4172-84-PNZ	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	New Zealand application no. 542886

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-84-PSG	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Singapore application no. 2005-06561-0 Patent No. 116214 granted 2/29/08; expires 5/14/24
4172-84-PSG-DIV	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	Singapore application no. 2007-03595-9
4172-84-PZA	Treatment Of T-Cell Mediated Diseases; David Bar-Or Raphael Bar-Or Richard Shimonkevitz	Treatment of T-cell mediated diseases using certain diketopiperazines	South Africa application no. 2005/09184 Patent granted; expires 5/14/24
4172-85PROV	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	Use of diketopiperazines for diagnosis and monitoring of diseases. Methods of diagnosis and monitoring of multiple sclerosis, Alzheimer=s disease and ischemia, particularly placental ischemia	Provisional application no. 60/489,039, filed July 21, 2003 Procedures complete
4172-85PROV-1	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	Use of diketopiperazines (N-terminal and C-terminal) and resultant truncated proteins for diagnosis and monitoring of diseases. Methods of diagnosis and monitoring of multiple sclerosis, Alzheimer=s disease and ischemia, particularly placental ischemia	Provisional application no. 60/503,185, filed September 15, 2003 Procedures complete

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-85	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	Use of diketopiperazines (N-terminal and C-terminal), resultant truncated proteins and other markers for diagnosis and monitoring of diseases. Methods of diagnosis and monitoring of multiple sclerosis, Alzheimer=s disease and ischemia, particularly placental ischemia	Nonprovisional U.S. application 10/679,699; filed October 2, 2003
4172-85-PCT	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	Use of diketopiperazines (N-terminal and C-terminal), resultant truncated proteins and other markers for diagnosis and monitoring of diseases. Methods of diagnosis and monitoring of multiple sclerosis, Alzheimer=s disease and ischemia, particularly placental ischemia	PCT application 03/31,226; filed October 2, 2003 Published as PCT WO 04/030522 Nationalized
4172-85-PAU	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	See 4172-85-PCT	Australian application No. 2003 279 761
4172-85-PCA	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	See 4172-85-PCT	Canadian application Serial No. 2,500,652

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-85-PEP	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	See 4172-85-PCT	EP application no. 03773099,1-2305
4172-85-PEPHK	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	See 4172-85-PEP	HK application no. 06103091.6 corresponding to 4172-85-PEP; filed 3/10/06
4172-85-PIP	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	See 4172-85-PCT	Japanese application 2005-500360
4172-85-PNZ	Use Of Diketopiperazines For Diagnosis And Monitoring Of Diseases; David Bar-Or Raphael Bar-Or	See 4172-85-PCT	New Zealand application no. 539735
4172-87PROV	N-Acetyl-L-Aspartate As a Therapeutic; David Bar-Or Leonard T. Rael	Use of NAA to inhibit inflammation and to treat inflammation and diseases or conditions involving, caused by, or exacerbated by, inflammation	Provisional application 60/506,323 filed September 25, 2003

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-87	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	Use of N-acyl-L-aspartic acid derivatives to treat inflammation and inflammatory diseases or conditions and to treat diseases and conditions involving, caused by, or exacerbated by, cell proliferation	Nonprovisional US application 10/949,715, filed September 24, 2004 Abandoned
4172-87-DIV	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	Use of N-acyl-L-aspartic acid derivatives to treat inflammation and inflammatory diseases or conditions and to treat diseases and conditions involving, caused by, or exacerbated by, cell proliferation	Nonprovisional US application 11/966,293, filed 12/28/07
4172-87-PCT	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	Use of N-acyl-L-aspartic acid derivatives to treat inflammation and inflammatory diseases or conditions and to treat diseases and conditions involving, caused by, or exacerbated by, cell proliferation	PCT application filed September 24, 2004; published as WO 2005/030083 on April 7, 2005 Nationalized
4172-87-PAU	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	Australian application no. 2004275821; filing date 9/24/04
4172-87-PCA	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	Canadian application no. 2,538,352; filing date 9/24/04

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-87-PCN	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	Chinese application no. 200480034908.9; filing date 9/24/04
4172-87-PCN-HK	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	Hong Kong application no. 07106768.0
4172-87-PEP	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	EP application no. 04789036.3; filing date 9/24/04
4172-87-PJP	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	Japanese application no. 2006-528239; filing date 9/24/04
4172-87-PKR	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	S. Korean application no. 10-2006-7005801; filing date 9/24/04

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-87-PNZ	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	New Zealand application 545854; filed 9/24/04
4172-87-PSG	Methods And Products Which Utilize N-Acyl-L-Aspartic Acid; David Bar-Or Leonard T. Rael	National phase of 4172-87-PCT	Singapore application no. 200601717-2; filing date 9/24/04 Patent No. 120548 granted March 30, 2007; expires 9/24/24
4172-88PROV	Improved Albumin Composition And Method Of Preparation; David Bar-Or Raphael Bar-Or	Method of preparing improved albumin compositions by reducing albumin to remove cysteine from cysteinylated albumin species to restore oxidant capacity	Provisional application 60/544,573, filed February 13, 2004 Abandoned
4172-89PROV	Method Of Synthesizing Diketopiperazines; Nagaraja K.R. Rao	Method of synthesizing diketopiperazines	Provisional application 60/684,750, filed on May 25, 2005 Abandoned
4172-90PROV	Quantification Of Proteins; David Bar-Or Raphael Bar-Or Leonard T. Rael	Method and kit for determining the quantity of proteins that comprise post-translationally modified cysteine sulphydryl groups. Method and kit for determining the quantity of proteins that have no cysteines in their amino acid sequence	Provisional application 60/658,856, filed March 3, 2005

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-90	Quantification Of Proteins; David Bar-Or Raphael Bar-Or Leonard T. Rael	Method and kit for determining the quantity of proteins that comprise post-translationally modified cysteine sulphydryl groups. Method and kit for determining the quantity of proteins that have no cysteines in their amino acid sequence	Nonprovisional U.S. application 11/368,031, filed March 3, 2006
4172-90-PCT	Quantification Of Proteins; David Bar-Or Raphael Bar-Or Leonard T. Rael	Method and kit for determining the quantity of proteins that comprise post-translationally modified cysteine sulphydryl groups. Method and kit for determining the quantity of proteins that have no cysteines in their amino acid sequence	PCT application PCT/US2006/007574, filed March 3, 2006 Nationalized
4172-90-PCA	Quantification Of Proteins; David Bar-Or Raphael Bar-Or Leonard T. Rael	Method and kit for determining the quantity of proteins that comprise post-translationally modified cysteine sulphydryl groups. Method and kit for determining the quantity of proteins that have no cysteines in their amino acid sequence	Canadian application; filed March 3, 2006
4172-91PROV	Treatment Of Ocular Diseases And Conditions; David Bar-Or	Use of danazol, trilostane and related compounds to treat angiogenic eye diseases, including primarily macular degeneration	US provisional application 60/698,723, filed July 12, 2005 Procedures complete
4172-91	Methods And Products For Treatment Of Diseases; David Bar-Or	Use of danazol, trilostane and related compounds to treat angiogenic and inflammatory eye and brain diseases and neurodegenerative diseases and products suitable for use on eyes	US nonprovisional application 11/457,063, filed July 12, 2006

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-91-PCT	Methods And Products For Treatment Of Diseases; David Bar-Or	Use of danazol, trilostane and related compounds to treat angiogenic and inflammatory eye and brain diseases and neurodegenerative diseases and products suitable for use on eyes	PCT application PCT/US2006/027480, filed July 12, 2006 Published as WO 2007/009087 Nationalized
4172-91-PCN	Methods And Products For Treatment Of Diseases; David Bar-Or	Use of danazol, trilostane and related compounds to treat angiogenic and inflammatory eye and brain diseases and neurodegenerative diseases and products suitable for use on eyes	Chinese application 200680033378.5; filed July 12, 2006
4172-91-PEP	Methods And Products For Treatment Of Diseases; David Bar-Or	Use of danazol, trilostane and related compounds to treat angiogenic and inflammatory eye and brain diseases and neurodegenerative diseases and products suitable for use on eyes	EP application 1919290; filed July 12, 2006
4172-91-PJP	Methods And Products For Treatment Of Diseases; David Bar-Or	Use of danazol, trilostane and related compounds to treat angiogenic and inflammatory eye and brain diseases and neurodegenerative diseases and products suitable for use on eyes	Japanese application 2008-521661; filed July 12, 2006
4172-92PROV	Method Of Isolating Apolipoprotein A1; David Bar-Or Raphael Bar-Or Leonard T. Rael	Method of isolating and purifying apolipoprotein A1	Provisional application 60/658,977, filed March 3, 2005 Abandoned

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-93PROV	Treatment Of Angiogenic Diseases; David Bar-Or	Inhibition of angiogenesis and treatment of angiogenic diseases and conditions using certain diketopiperazines. Also pharmaceutical compositions comprising the diketopiperazines	Provisional application 60/663,003, filed March 18, 2005 Abandoned; replaced by 4172-93PROV-1
4172-93PROV-1	Treatment Of Angiogenic Diseases; David Bar-Or	Inhibition of angiogenesis and treatment of angiogenic diseases and conditions using certain diketopiperazines. Also pharmaceutical compositions comprising the diketopiperazines	Provisional application 60/775,922, filed February 22, 2006 Abandoned; replaced by 4172-103PROV
4172-94PROV	Uses Of Diketopiperazines; David Bar-Or	Use of certain diketopiperazines to inhibit immune responses, treat T-cell mediated diseases, inhibit activation of T-cells and monocytes, inhibit proliferation and adhesion of lymphocytes, inhibit inflammation and treat inflammatory diseases.	Provisional application 60/662,966, filed March 18, 2005 Abandoned; replaced by 4172-94PROV-1
4172-94PROV-1	Uses Of Diketopiperazines; David Bar-Or	Use of certain diketopiperazines to inhibit immune responses, treat T-cell mediated diseases, inhibit activation of T-cells and monocytes, inhibit proliferation and adhesion of lymphocytes, inhibit inflammation and treat inflammatory diseases.	Provisional application 60/776,153, filed February 22, 2006 Abandoned; replaced by 4172-103PROV
4172-95PROV	Treatment Of Brain Tumors; David Bar-Or	Use of danazol, trilostane and related compounds to treat brain tumors	Provisional application 60/711,158, filed August 24, 2005 Procedures completed (see 4172-91 and 4172-91-PCT)

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-96PROV	Treatment Of Neurodegenerative Diseases; David Bar-Or	Use of danazol, trilostane and related compounds to treat neurodegenerative diseases and conditions, including multiple sclerosis	Provisional application 60/711,157, filed August 24, 2005 Procedures completed (see 4172-91 and 4172-91-PCT)
4172-98PROV	Method Of Synthesizing Diketopiperazines; Nagaraja K.R. Rao	Method of synthesizing diketopiperazines; see 4172-89PROV	Provisional application 60/776,601, filed on February 22, 2006 Abandoned
4172-99PROV	Diagnostic assay; David Bar-Or Leonard Rael	Use of general esterase levels to diagnose diseases	Provisional application no. 60/799,431; filed May 10, 2006 Abandoned
4172-100PROV	Diagnostic assay; David Bar-Or Leonard Rael	Use of paraoxonase levels to diagnose certain diseases	Provisional application no. 60/799,361; filed May 10, 2006 Abandoned
4172-103PROV	Methods And Compounds For Treatment of Cancer; David Bar-Or	Diketopiperazines of formula I and pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or produgs thereof, as the active ingredient. Also, a method of treating a cancer in an animal with the diketopiperazines, or pharmaceutically-acceptable salts or produgs thereof. In addition, a method of inhibiting the production, release or both of matrix metalloproteinase-9 from cells using the diketopiperazines or pharmaceutically-acceptable salts or produgs thereof.	Provisional application no. 60/940,889; filed May 30, 2007 Abandoned in favor of 4172-104PROV

FILE NO.	TITLE	DESCRIPTION/COMMENTS	STATUS (PENDING UNLESS OTHERWISE INDICATED)
4172-104PROV	Methods And Compounds For Treatment of Cancer; David Bar-Or	Diketopiperazines of formula I and pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. Also, a method of treating a cancer in an animal with the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof. In addition, a method of inhibiting the production, release or both of matrix metalloproteinase-9 from cells using the diketopiperazines or pharmaceutically-acceptable salts or prodrugs thereof.	Provisional application no. 61/056,379; filed May 27, 2008